Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer

PURPOSE: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules. EXPERIMENTAL DESIGN: Patients with progressive solid tumor malignancies were treated with 17-...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Solit, David B., Ivy, S. Percy, Kopil, Catherine, Sikorski, Rachel, Morris, Michael J., Slovin, Susan F., Kelly, W. Kevin, DeLaCruz, Anthony, Curley, Tracy, Heller, Glenn, Larson, Steven, Schwartz, Lawrence, Egorin, Merrill J., Rosen, Neal, Scher, Howard I.
Formato: Artigo
Idioma:Inglês
Publicado em: 2007
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203693/
https://ncbi.nlm.nih.gov/pubmed/17363532
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-06-1863
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados